To determine if there are ways to predict which men will get prostate cancer, if there are ways to predict how a prostate cancer will develop (for example, slow or rapid growth) and why there are differences in prostate cancer among men from different ethnic backgrounds.
We will expand and enhance our cohort of men at risk for prostate cancer by increasing enrollment of men at greater risk of prostate cancer and at a higher risk of high-grade prostate cancer.
a. We will maintain follow-up and accrual of multi-ethnic, multi-racial cohort of men in the current SABOR cohort for prostate cancer outcomes
b. Maintain collection of wide range of biologic samples for this cohort and perform validation studies as new biomarkers are identified. Biologics gathered on patient visits are serum (at enrollment, annually and cancer dx.), whole blood, buffy coat (enrollment and cancer dx.) and PSA (enrollment, annually, and cancer dx.).
c. Maintain collection of extensive demographic and other risk factor data. Data elements gathered on cohort are date of birth, race, ethnicity, family history of PCA and other cancers, medical history, surgical history, current medications, AUA score, diabetes status, NSAID usage, prostate-related procedures and treatments
d. Additional biologics will be collected for prospective biomarker studies. Examples may include post-DRE urine collections or blood specimens with specific processing requirements.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.